<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Med (Wars)</journal-id><journal-id journal-id-type="iso-abbrev">Open Med (Wars)</journal-id><journal-id journal-id-type="publisher-id">med</journal-id><journal-id journal-id-type="pmc">med</journal-id><journal-title-group><journal-title>Open Medicine</journal-title></journal-title-group><issn pub-type="epub">2391-5463</issn><publisher><publisher-name>De Gruyter Open</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5984478</article-id><article-id pub-id-type="publisher-id">med-2018-0013</article-id><article-id pub-id-type="doi">10.1515/med-2018-0013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Articles</subject></subj-group></article-categories><title-group><article-title>The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhihui</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Qinge</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xiaoyan</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jianzhong</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="j_med-2018-0013_aff_002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shihong</given-names></name><xref ref-type="corresp" rid="med-2018-0013_cor_001">*</xref><xref ref-type="aff" rid="j_med-2018-0013_aff_001"><sup>1</sup></xref></contrib><aff id="j_med-2018-0013_aff_001"><label>1</label><institution>Department of Obstetrics and Gynecology Affiliated Hospital of Beihua University</institution>, <city>Jilin</city>, <addr-line>132000</addr-line>, <country country="CN">China</country></aff><aff id="j_med-2018-0013_aff_002"><label>2</label><institution>Department of Gynecology Weihai Municipal Hospital</institution>, <city>Shandong</city>, <addr-line>264200</addr-line>, <country country="CN">China</country></aff></contrib-group><author-notes><corresp id="med-2018-0013_cor_001"><label>*</label> E-mail: <email xlink:href="mailto:zhan8@qq.com">zhan8@qq.com</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><fpage>83</fpage><lpage>89</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Zhihui Li et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Zhihui Li et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.</license-p></license></permissions><abstract><title>Abstract</title><p>This study investigated the effect of radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer.</p><sec id="j_med-2018-0013_s_006"><title>Methods</title><p>Seventy-five patients with advanced ovarian cancer were grouped into observation (n = 36) and control (n = 37) groups according to different treatment methods. The age of the patients in the control and the experimental groups were (55 + 11) and (53 + 12) years old, respectively. The control group was received chemotherapy alone (paclitaxel + cisplatin chemotherapy), and on the basis of systemic chemotherapy, the observation group was administered therapy in conjunction with abdominal pelvic radiofrequency hyperthermia.</p></sec><sec id="j_med-2018-0013_s_007"><title>Results</title><p>The tumor remission rate, ascites, serum CA125 levels, pain control, quality of life enhancement, III+IV bone marrow suppression and improvement of gastrointestinal reaction in the observation group were better than those of the control group (all P&#x0003c; 0.05).</p></sec><sec id="j_med-2018-0013_s_008"><title>Conclusion</title><p>Radiofrequency hyperthermia combined with chemotherapy in the treatment of advanced ovarian cancer has significantly improved the tumor remission rate, ascite control and CA125 levels, and substantially reduced the gastrointestinal reaction and bone marrow suppression rate, which is worthy of intensive clinical application.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Ovarian cancer</kwd><kwd>Radiofrequency hyperthermia</kwd><kwd>Drug therapy</kwd><kwd>Paclitaxel</kwd></kwd-group><counts><page-count count="7"/></counts></article-meta></front><body><sec id="j_med-2018-0013_s_001"><label>1</label><title>Introduction</title><p>Ovarian cancer is one of the most common malignant tumors of the female reproductive system, and it is the most common skin cancer [<xref rid="j_med-2018-0013_ref_001" ref-type="bibr">1</xref>]. Because of the special location, complicated anatomy and function of the ovary, the onset is occult, and the early symptoms of the patient are atypical or not obvious, and the early diagnosis is very difficult [<xref rid="j_med-2018-0013_ref_002" ref-type="bibr">2</xref>,<xref rid="j_med-2018-0013_ref_003" ref-type="bibr">3</xref>]. Although carbohydrate antigen-125 (CA125) and human epididymis secretory protein 4 (HE4) were already used for early diagnosis of ovarian cancer [<xref rid="j_med-2018-0013_ref_004" ref-type="bibr">4</xref>], which is highest in mortality rate among all gynecological tumors [<xref rid="j_med-2018-0013_ref_005" ref-type="bibr">5</xref>] . About two thirds of ovarian cancer patients come to the hospital for advanced symptoms every year. After treatment, the condition has been improved, but the recurrence or metastasis of the tumor leads to the failure of most of the patients, resulting in death. Radiofrequency hyperthermia, as a new therapy for cancer, cannot only kill the tumor but also damage the normal tissue by radiofrequency wave heating, and its treatment effect is obvious [<xref rid="j_med-2018-0013_ref_006" ref-type="bibr">6</xref>]. This study therefore set out to assess the curative effect of advanced ovarian cancer patients by radiofrequency hyperthermia combined with chemotherapy regimens in 73 cases of ovarian cancer patients.</p></sec><sec id="j_med-2018-0013_s_002"><label>2</label><title>Materials and methods</title><sec id="j_med-2018-0013_s_002_s_001"><label>2.1</label><title>General information</title><p>A total of 73 patients with advanced ovarian cancer admitted in our hospital from October 2013 to August 2015 were divided into 37 groups, 36 cases in the control group and two cases in the experimental group. The age of the patients was (55 + 11) and (53 + 12) in the control and the experimental groups, respectively.</p><p>Pathological type (control/ experimental cases per each group, respectively):</p><p>20/21 cases of serous adenocarcinoma,4/5 cases of mucinous adenocarcinoma, 3/2 cases of endometrial adenocarcinoma, 3/4 cases of clear cell carcinoma, 5/3 cases of squamous cellcarcinoma and 2/1 cases of undifferentiated carcinoma.</p><p>Clinical staging of ovarian carcinoma (control / experimental groups, respectively): 9/8 cases of stage IIIA, 12/13 cases of stage IIIB, 16/15 cases of stage IV; KPS scores were &#x0003e;67.</p><p>Routine examination was normal in the two groups prior to beginning of the treatment. Furthermore, the general data of the experimental group and the control group were not significantly different (<italic>P</italic>&#x0003e;0.05).</p><p>Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors&#x02019; institutional review board or equivalent committee.</p><p>Informed consent: Informed consent has been obtained from all individuals included in this study.</p></sec><sec id="j_med-2018-0013_s_002_s_002"><label>2.2</label><title>Methods</title><p>Control group: Thirty seven patients served as the control group was treated with routine chemotherapy only. The patients were treated with anti-allergic drugs to prevent allergic reactions in the course of chemotherapy before the application of chemotherapy drugs. Cisplatin (75 mg/ m2) and paclitaxel (135 mg/m2) were received over for 24 h for 21 cycles of chemotherapy, with 6 courses of treatment. Meanwhile, the patients in the control group were monitored closely for any changes in the rate of treatment and blood pressure to prevent the patients who are at a high risk of shock and even death due to abnormal blood pressure.</p><p>Experimental group: Patients with a variety of pathologically confirmed cancer were treated with radiofrequency hyperthermia and chemotherapy for 7 days, and then underwent hyperthermia chemotherapy for 3 days. Rotational program of hyperthermia and chemotherapy treatment were performed for 2-3 weeks.</p><p>In this study, the SR1000 tumor radiofrequency hyperthermia apparatus (Xianke, Shenzhen, China) was adopted, and the non-contact treatment method was conducted. The tissue was heated by radiofrequency wave, the temperature was set at (42.5-43.5), and the duration was 60-120 min.</p><p>In the course of the 8 cycles of treatment, each group received 1 curative evaluation after 2 cycles of treatment, 6D / cycle [<xref rid="j_med-2018-0013_ref_003" ref-type="bibr">3</xref>]. The evaluation indexes of the experimental group and the control group were compared.</p></sec><sec id="j_med-2018-0013_s_002_s_003"><label>2.3</label><title>Assessment criteria</title><p>The composite of chemotherapy in patients with solid tumors was evaluated according to the changes of the tumor (30%), clinical symptoms (15%), physical condition (15%), and survival rate (40%), assigned a score of 0-100 as follows: invalid (&#x0003c;25), stable (25~49) and effective (50~75) and effective (&#x0003e;75) 4 grades, tumor remission rate, which equals to effective remission rate and effective remission rate.</p><p>Bone marrow suppression: it was divided into 4 levels: I, IV, IV, and graded by evaluation of thrombocytopenia and decrease of wbc [<xref rid="j_med-2018-0013_ref_008" ref-type="bibr">8</xref>].</p><p>Gastrointestinal reaction: the reaction includes the following symptoms: constipation, diarrhea, vomiting, nausea and severe degree I ~ IV [<xref rid="j_med-2018-0013_ref_008" ref-type="bibr">8</xref>].</p><p>Results of CA125 biomarker for early detection [<xref rid="j_med-2018-0013_ref_009" ref-type="bibr">9</xref>] and pain control are divided into 3 categories. Reference WHO cancer leachate treatment standard was employed to divide the assessment for the improvement of the quality of life in ascites in combination with Karnofsky integral [<xref rid="j_med-2018-0013_ref_010" ref-type="bibr">10</xref>,<xref rid="j_med-2018-0013_ref_011" ref-type="bibr">11</xref>] standard (<xref ref-type="table" rid="j_med-2018-0013_tab_001">Table 1</xref>).</p><table-wrap id="j_med-2018-0013_tab_001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Evaluation form of CA125 test results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Experimental / control groups</th><th align="left" rowspan="1" colspan="1">Effective / Very effective</th><th align="left" rowspan="1" colspan="1">Improvement / Stability</th><th align="left" rowspan="1" colspan="1">Invalid</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CA125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Detection level of CA125</td><td align="left" rowspan="1" colspan="1">Decrease &#x0003e;50% or normal</td><td align="left" rowspan="1" colspan="1">Rise &#x0003c;25% or &#x0003c;50%</td><td align="left" rowspan="1" colspan="1">Elevation &#x0003e;50%</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (days)</td><td align="left" rowspan="1" colspan="1">&#x02264; 4</td><td align="left" rowspan="1" colspan="1">Less than or equal to 4</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Ascites</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ascite ratio before and after</td><td align="left" rowspan="1" colspan="1">&#x0003e;1/2</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">&#x02264;1/2 or elevation</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (weeks)</td><td align="left" rowspan="1" colspan="1">&#x0003e;4</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Life improvement</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Score before treatment (score)</td><td align="left" rowspan="1" colspan="1">&#x0003e;20</td><td align="left" rowspan="1" colspan="1">&#x02265;10 and s19</td><td align="left" rowspan="1" colspan="1">&#x0003c;10</td></tr><tr><td align="left" rowspan="1" colspan="1">Pain symptom control</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Taking a painkiller before treatment</td><td align="left" rowspan="1" colspan="1">Greater than 1/3</td><td align="left" rowspan="1" colspan="1">&#x0003e;1/3 and &#x0003c;2/3</td><td align="left" rowspan="1" colspan="1">Greater than 2/3</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration (days)</td><td align="left" rowspan="1" colspan="1">&#x02265;3</td><td align="left" rowspan="1" colspan="1">&#x02265;3</td><td align="left" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap id="j_med-2018-0013_tab_002" orientation="portrait" position="float"><label>Table 2</label><caption><p>The comparison of efficacy between traditional method (control group) and combined therapy (experimental group).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Tumor alleviation</th><th align="left" rowspan="1" colspan="1">Ascite regulation</th><th align="left" rowspan="1" colspan="1">CA125 control</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Experimental group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">30 (83.3)</td><td align="left" rowspan="1" colspan="1">27 (75.0)</td><td align="left" rowspan="1" colspan="1">30 (83.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">16 (43.2)</td><td align="left" rowspan="1" colspan="1">11 (29.7)</td><td align="left" rowspan="1" colspan="1">18 (48.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">X<sup>2</sup></td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">12.58</td><td align="left" rowspan="1" colspan="1">14.98</td><td align="left" rowspan="1" colspan="1">9.75</td></tr><tr><td align="left" rowspan="1" colspan="1">P -value</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.05</td></tr></tbody></table></table-wrap></sec><sec id="j_med-2018-0013_s_002_s_004"><label>2.4</label><title>Statistical method</title><p>All patients were followed up from the first treatment, and the survival rate was calculated by kaplan-meier method. Single-factor analysis was performed with the log-rank. All the data were analyzed by SPSS 16 software., Qualitative data were verified by Pearson&#x02019;s chi-squared test (x<sup>2</sup>) of statistics; A P- value of less than 0.05 was considered statistically significant.</p></sec></sec><sec id="j_med-2018-0013_s_003"><label>3</label><title>Results</title><sec id="j_med-2018-0013_s_003_s_001"><label>3.1</label><title>Comparison of the short-term curative effect between the experimental and control groups</title><p>Compared to the control group, the tumor control rate of ascites in the experimental group (combined chemotherapy), has been effectively alleviated, and CA125 level inspection indications have been significantly improved (<italic>P</italic>&#x0003c;0.05).</p></sec><sec id="j_med-2018-0013_s_003_s_002"><label>3.2</label><title>Comparison of the toxicity and side effects of the experimental and control groups</title><p>No significant differences in the nausea and vomiting, white blood cells (WBCs), serum creatinine and fatty induration were found between the two groups (<xref ref-type="table" rid="j_med-2018-0013_tab_003">Table 3</xref>).</p><table-wrap id="j_med-2018-0013_tab_003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Toxicity and side effects of the experimental group in comparison with the control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Nausea and vomiting</th><th align="left" rowspan="1" colspan="1">WBCs</th><th align="left" rowspan="1" colspan="1">Serum creatinine</th><th align="left" rowspan="1" colspan="1">Fatty induration</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Experimental group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></sec><sec id="j_med-2018-0013_s_003_s_003"><label>3.3</label><title>Comparison of pain control between the two groups</title><p>In this study, the Fisher exact probability method was used to verify the statistical significance (P&#x0003c;0.05) as shown in <xref ref-type="table" rid="j_med-2018-0013_tab_004">Table 4</xref>. There were 10 patients with pain control in the experimental group, accounting for 77.8%. The control group received 4 cases of pain control, accounting for 54.1%.</p><table-wrap id="j_med-2018-0013_tab_004" orientation="portrait" position="float"><label>Table 4</label><caption><p>Pain control in the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Significant effect</th><th align="left" rowspan="1" colspan="1">Effective</th><th align="left" rowspan="1" colspan="1">No effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Experimental group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">17</td></tr></tbody></table></table-wrap></sec><sec id="j_med-2018-0013_s_003_s_004"><label>3.4</label><title>Comparison of the quality of life in the two groups</title><p>As presented in <xref ref-type="table" rid="j_med-2018-0013_tab_005">Table 5</xref>, the quality of life in the experimental group was substantially improved in 24 cases, accounting for 66.7%, while the quality of life in the control group was significantly enhanced in 6 cases, constituting 27.3% (<italic>P</italic>&#x0003c;0.05).</p><table-wrap id="j_med-2018-0013_tab_005" orientation="portrait" position="float"><label>Table 5</label><caption><p>Quality of life in the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Significant effect</th><th align="left" rowspan="1" colspan="1">Effective</th><th align="left" rowspan="1" colspan="1">No effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Experimental group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">27</td></tr></tbody></table></table-wrap><table-wrap id="j_med-2018-0013_tab_006" orientation="portrait" position="float"><label>Table 6</label><caption><p>Comparison of myelosuppression and gastrointestinal response between the two groups [case (%)].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Groups</th><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Marrow suppression of grade III + IV</th><th align="left" rowspan="1" colspan="1">Third or fourth degree gastrointestinal response</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Experimental group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">4 (11.1)</td><td align="left" rowspan="1" colspan="1">8 (22.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">17 (45.9)</td><td align="left" rowspan="1" colspan="1">18 (48.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">X<sup>2</sup></td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">10.81</td><td align="left" rowspan="1" colspan="1">5.56</td></tr><tr><td align="left" rowspan="1" colspan="1">P-value</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.05</td></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Survival rate</bold>:</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>Sample</bold></td><td align="left" rowspan="1" colspan="1"><bold>Survival rate</bold></td><td align="left" rowspan="1" colspan="1"><bold>Death rate</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">Case group</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">23<xref ref-type="table-fn" rid="j_med-2018-0013_fn_001"><sup>*</sup></xref></td><td align="left" rowspan="1" colspan="1">13</td></tr></tbody></table><table-wrap-foot><fn id="j_med-2018-0013_fn_001"><label>*</label><p>Compared with the control group, P&#x0003c;0.05</p></fn></table-wrap-foot></table-wrap></sec><sec id="j_med-2018-0013_s_003_s_005"><label>3.5</label><title>Comparison of myelosuppression stages III and IV disease and gastrointestinal response levels between the two groups</title><p>The experimental group with substantial difference in the myelosuppression stages of disease (III + IV) and gastrointestinal reaction levels compared to the control one (<italic>P</italic>&#x0003c;0.05) (<xref ref-type="table" rid="j_med-2018-0013_tab_005">Table 5</xref>).</p><p>Mild scalds was occurred in local skin of 4 patients within the control group before heat treatment, but by wiping the area of the scalds with ointment and reducing the temperature properly, it was cured within a week.</p></sec></sec><sec id="j_med-2018-0013_s_004"><label>4</label><title>Discussion</title><p>The early diagnosis of ovarian cancer is difficult and the clinical symptoms of advanced stage are confirmed. The mortality rate is relatively high [<xref rid="j_med-2018-0013_ref_012" ref-type="bibr">12</xref>], meanwhile; the special anatomic location of the ovary leads to an increase in the probability of diffuse metastasis of the abdomen [<xref rid="j_med-2018-0013_ref_013" ref-type="bibr">13</xref>].</p><p>There are many ways to treat ovarian cancer; however, only a few methods are effective. The overall efficiency is still no more than 30% [<xref rid="j_med-2018-0013_ref_014" ref-type="bibr">14</xref>], and the patients have a high recurrence rate within a period of time after operation. Intraperitoneal direct transfer is the main route [<xref rid="j_med-2018-0013_ref_015" ref-type="bibr">15</xref>], and the invasion of deep tissue is rare. The scheme of intraperitoneal thermal chemotherapy is very effective in killing cancer cells [<xref rid="j_med-2018-0013_ref_016" ref-type="bibr">16</xref>].</p><p>In recent years, it has become a new topic to investigate a regimen that can effectively control ovarian cancer without adverse effects to a certain extent during the treatment <xref rid="j_med-2018-0013_ref_017" ref-type="bibr">[17]</xref>.</p><p>In this study, the experimental group was received radiofrequency hyperthermia combined with chemotherapy, while the control group was treated by chemotherapy alone.</p><p>The patients in the experimental group have a higher tumor remission rate of ascites and examination index than those of the control group, and the toxicities of the pointer patients are lower than that of the control group.</p><p>Our results match those observed in earlier studies [<xref rid="j_med-2018-0013_ref_018" ref-type="bibr">18</xref>].</p><p>It has been reported that RF hyperthermia heating plays an important role in tumor therapy scheme, promotion of chemotherapy drugs and, inhibition of DNA repair [<xref rid="j_med-2018-0013_ref_019" ref-type="bibr">19</xref>] and multidrug resistance P-glycoprotein expression, meanwhile, it can improve the efficacy of chemotherapy.</p><p>It has been reported that radiofrequency hyperthermia and other hyperthermia treatments play a significant role in tumor treatment, which is more obvious in promoting addition reaction between chemotherapy drugs and cancer cell DNA.</p><p>DNA repair is inhibited by addition reaction of cancer cell DNA, and increases the addition reaction to inhibit the expression of multidrug resistant p-glycoprotein. Thereby, chemotherapeutic efficacy of ovarian cancer patients has been improved [<xref rid="j_med-2018-0013_ref_019" ref-type="bibr">19</xref>].</p><fig id="j_med-2018-0013_fig_001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Kaplan-Merier survival curve</p></caption><graphic xlink:href="med-13-083-g001"/></fig><p>In addition, a disorder of immune Th1/Th2 cytokines in the patients with ovarian cancer in peripheral blood leads to the immune escape of tumor cells [<xref rid="j_med-2018-0013_ref_021" ref-type="bibr">21</xref>] of the expression of heat shock proteins in patients during radiofrequency hyperthermia enhances the antitumor activity of chemotherapeutic drugs and elicits the immune surveillance function.</p></sec><sec id="j_med-2018-0013_s_005"><label>5</label><title>Conclusion</title><p>Radiofrequency hyperthermia [<xref rid="j_med-2018-0013_ref_022" ref-type="bibr">22</xref>] as a new cancer treatment, promotes the greater omentum to absorb drugs, improves the utilization rate of chemotherapy drugs. Moreover, it can effectively kill cancer cells in abdominal cavity [<xref rid="j_med-2018-0013_ref_023" ref-type="bibr">23</xref>,<xref rid="j_med-2018-0013_ref_024" ref-type="bibr">24</xref>]. Previous studies have found that cisplatin has synergistic effects with hyperthermia with no threshold effect drug [<xref rid="j_med-2018-0013_ref_006" ref-type="bibr">6</xref>]. Its main target is DNA, which acts on DNA strand and intra-strand junction, forming DDP~DNA complex, interfering with DNA replication, or combining with nuclear protein and cytoplasmic protein.</p><p>Hyperthermia hinders the repair of DNA damage induced by cisplatin and improves the utilization rate of cisplatin.</p><p>The machine SR1000 tumor radio-frequency hyperthermia machine uses non-contact therapy to heat the tissue to the temperature that can kill the tumor cells. It can kill the tumor cells without damaging the normal tissues.</p><p>There were 4 cases of fatty induration in the experimental group, accounting for 11.1%, which was lower than that of RF-8.</p><p>Radiofrequency hyperthermia combined with chemotherapy is more effective treatment and results in vascular changes in the tumor tissue and temperature differences.</p><p>Normal tissue can tolerate high temperature for a long period of time 42.5-43.5 (safety limit is 45 - 1 DEG C), thereby killing tumor cells without affecting normal cells.</p><p>Hyperthermia does not cause adverse reactions, such as myelosuppression or alopecia. Since the number of samples collected in our hospital is smaller after grouping, the results of this clinical observation need to be further verified. It needs to be confirmed by large sample data in order to obtain more reliable indicators.</p><p>In summary, radiofrequency hyperthermia combined with chemotherapy is more effective chemotherapy in the treatment of patients with advanced ovarian cancer, considers an alternative for anticancer drug resistance cases, increases the susceptibility of patients for the treatment, and reduces the toxicity of patients and promotes the rehabilitation of patients, which is worthy of comprehensive clinical application.</p></sec></body><back><fn-group><fn fn-type="other" id="j_med-2018-0013_fn_002"><p><bold>Declaration of interest</bold>: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.</p></fn></fn-group><ack id="j_med-2018-0013_ack_001"><title>Acknowledgements</title><p>The present study was funded by the Jilin provincial health science research plan (2014Z081)</p></ack><ref-list><title>References</title><ref id="j_med-2018-0013_ref_001"><label>[1]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Cao</surname><given-names>X.Y.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><etal/><article-title>Nedaplatin Combined with gemcitabine in the treatment of elderly patients with recurrent ovarian cancer the curative effect of China</article-title><source>J. gerontol.</source><year>2012</year><volume>32</volume><fpage>670</fpage><lpage>672</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_002"><label>[2]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Oberaigner</surname><given-names>W.</given-names></name><name><surname>Minicozzi</surname><given-names>P.</given-names></name><name><surname>Bielskalasota</surname><given-names>M.</given-names></name><etal/><article-title>Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade</article-title><source>J.Acta. Oncol..</source><year>2012</year><volume>51</volume><fpage>441</fpage><lpage>53</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_003"><label>[3]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>CY.</given-names></name><article-title>The value of soluble B7-H4 in the diagnosis of early ovarian cancer</article-title><source>J. Chin. J. Mod. Med.</source><year>2014</year><volume>24</volume><fpage>107</fpage><lpage>109</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_004"><label>[4]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Whitehouse</surname><given-names>C.</given-names></name><name><surname>Solomon</surname><given-names>E.</given-names></name><article-title>Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening</article-title><source>J. Gynecol. Oncol.</source><year>2003</year><volume>88</volume><fpage>152</fpage><lpage>157</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_005"><label>[5]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wei</surname><given-names>LW.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><article-title>Research progress of multidrug resistance related signal transduction pathway and its targeted drugs in epithelial ovarian cancer</article-title><source>J. Clin.Oncol.</source><year>2016</year><volume>43</volume><fpage>396</fpage><lpage>399</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_006"><label>[6]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>F.</given-names></name><etal/><article-title>Effects of hyperthermia combined with hyperthermia on proliferation of human breast cancer cells</article-title><source>J. Chinese Journal of physical medicine and rehabilitation.</source><year>2014</year><volume>36</volume><fpage>577</fpage><lpage>582</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_007"><label>[7]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Zhou</surname><given-names>HM.</given-names></name><name><surname>Huang</surname><given-names>HF.</given-names></name><name><surname>Pan</surname><given-names>LY.</given-names></name><etal/><article-title>Clinical study of the change of serum CA125 value in judging the curative effect and prognosis of epithelial ovarian cancer</article-title><source>J. Chinese Journal of Practical Gynecology and obstetrics.</source><year>2008</year><volume>24</volume><fpage>204</fpage><lpage>206</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_008"><label>[8]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Zhu</surname><given-names>LN.</given-names></name><name><surname>Fan</surname><given-names>QX.</given-names></name><name><surname>Zong</surname><given-names>H.</given-names></name><etal/><article-title>Clinical application of hyperthermia combined with chemotherapy in advanced gastric cancer</article-title><source>J. Chinese Journal of physical medicine and rehabilitation.</source><year>2013</year><volume>35</volume><fpage>326</fpage><lpage>329</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_009"><label>[9]</label><element-citation publication-type="journal" publication-format="print"><name><surname>heng</surname><given-names>X.</given-names></name><name><surname>Gou</surname><given-names>HF.</given-names></name><name><surname>Liu</surname><given-names>JY.</given-names></name><etal/><article-title>Clinical significance of serum CA125 in diffuse malignant mesothelioma</article-title><source>J. SpringerPlus.</source><year>2016</year><volume>5</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_010"><label>[10]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><article-title>CNKI literature of TCM treatment of ascites cancer drug law research</article-title><source>J. Journal of traditional Chinese medicine information based on Chinese.</source><year>2014</year><volume>21</volume><fpage>22</fpage><lpage>25</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_011"><label>[11]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Timmermann</surname><given-names>C.</given-names></name><article-title>the Karnofsky scaleand the history of quality of life measurements in cancer trials</article-title><source>J. Chronic Illness.</source><year>2013</year><volume>9</volume><fpage>179</fpage><lpage>190</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_012"><label>[12]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Jacobs</surname><given-names>IJ.</given-names></name><name><surname>Menon</surname><given-names>U.</given-names></name><name><surname>Ryan</surname><given-names>A.</given-names></name><etal/><article-title>Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial</article-title><source>J. Lancet.</source><year>2016</year><volume>387</volume><fpage>945</fpage><lpage>956</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_013"><label>[13]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wu</surname><given-names>WH.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Cui</surname><given-names>MH.</given-names></name><article-title>Progress in the study of CD4+CD25+ regulatory T cells and ovarian cancer</article-title><source>J. Maternal and Child Health Care of China.</source><year>2016</year><volume>31</volume><fpage>3192</fpage><lpage>3195</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_014"><label>[14]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Li</surname><given-names>XH.</given-names></name><name><surname>Chen</surname><given-names>XJ.</given-names></name><name><surname>Ou</surname><given-names>WB.</given-names></name><etal/><article-title>Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis</article-title><source>J. The International Journal of Biochemistry and Cell Biology.</source><year>2013</year><volume>45</volume><fpage>979</fpage><lpage>986</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_015"><label>[15]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Lili</surname><given-names>LN.</given-names></name><name><surname>Matyunina</surname><given-names>LV.</given-names></name><name><surname>Walker</surname><given-names>DE.</given-names></name><etal/><article-title>Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis</article-title><source>J. Journal of Ovarian Research</source><year>2013</year><volume>6</volume><fpage>49</fpage><lpage>5249</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_016"><label>[16]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Zhang</surname><given-names>Y.</given-names></name><article-title>Effect of intraperitoneal hyperthermic perfusion chemotherapy on ovarian malignancies</article-title><source>J. Henan Medical Research.</source><year>2015</year><volume>24</volume><fpage>103</fpage><lpage>104</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_017"><label>[17]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name><article-title>cisplatin intraperitoneal perfusion combined with gemcitabine intravenous chemotherapy in the treatment of malignant ascites of ovarian cancer</article-title><source>J. Journal of Shanxi Medical Journal.</source><year>2010</year><volume>39</volume><fpage>531</fpage><lpage>532</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_018"><label>[18]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><etal/><article-title>Clinical observation of the effect of deep hyperthermia combined with chemotherapy on advanced ovarian cancer</article-title><source>J. Chinese Journal of clinicians (Electronic Edition).</source><year>2014</year><volume>8</volume><fpage>1997</fpage><lpage>2001</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_019"><label>[19]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><article-title>Application of hyperthermia in tumor therapy</article-title><source>J. Chinese Medical Journal</source><year>2004</year><volume>39</volume><fpage>8</fpage><lpage>11</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_020"><label>[20]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Muenyi</surname><given-names>CS.</given-names></name><name><surname>Trivedi</surname><given-names>AP.</given-names></name><name><surname>Helm</surname><given-names>CW.</given-names></name><etal/><article-title>Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells</article-title><source>J. Toxicological Sciences An Official Journal of the Society of Toxicology.</source><year>2014</year><volume>139</volume><fpage>74</fpage></element-citation></ref><ref id="j_med-2018-0013_ref_021"><label>[21]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Xin</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><etal/><article-title>Clinical study of Th1/Th2 cytokines in peripheral blood of patients with ovarian cancer</article-title><source>J. Journal of Practical Medicine.</source><year>2008</year><volume>24</volume><fpage>1154</fpage><lpage>1156</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_022"><label>[22]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/><article-title>Short-term therapeutic effect of radiofrequency hyperthermia combined with intraperitoneal hyperthermic perfusion chemotherapy on malignant peritoneal effusion</article-title><source>J. Chinese Journal of physical medicine and rehabilitation.</source><year>2006</year><volume>28</volume><fpage>786</fpage><lpage>787</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_023"><label>[23]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Nicoletto</surname><given-names>MO.</given-names></name><name><surname>Padrini</surname><given-names>R.</given-names></name><name><surname>Galeotti</surname><given-names>F.</given-names></name><etal/><article-title>Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer</article-title><source>J. Cancer Chemotherapy and Pharmacology.</source><year>2000</year><volume>45</volume><fpage>457</fpage><lpage>462</lpage></element-citation></ref><ref id="j_med-2018-0013_ref_024"><label>[24]</label><element-citation publication-type="journal" publication-format="print"><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Yamashiro</surname><given-names>H.</given-names></name><name><surname>Sawada</surname><given-names>T.</given-names></name><etal/><article-title>Therapeutic results and pharmacokinetics of combined used anticancer drug in intraperitoneal hyperthermo-chemotherapy (CHPP)</article-title><source>J. Gan to Kagaku Ryoho Cancer &#x00026; Chemotherapy</source><year>1990</year><volume>17</volume><fpage>1551</fpage></element-citation></ref></ref-list></back></article>